CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aura Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aura Biosciences Inc
80 Guest Street
Phone: (617) 500-8864p:617 500-8864 BOSTON, MA  01235  United States Ticker: AURAAURA
Business Summary
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board DavidJohnson 60 4/28/2021 1/5/2021
President, Chief Executive Officer, Director ElisabetDe Los Pinos 52 1/1/2019 1/1/2019
Interim Principal Financial Officer, Interim Principal Accounting Officer AmyElazzouzi 51 10/25/2024 10/25/2024
7 additional Officers and Directors records available in full report.

Business Names
Business Name
AURA
Aura Biosciences B.V.
Aura Biosciences GmbH
Aura Biosciences Securities Corporation

General Information
Number of Employees: 106 (As of 2/28/2025)
Outstanding Shares: 50,268,758 (As of 4/21/2025)
Shareholders: 53
Stock Exchange: NASD
Federal Tax Id: 320271970
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 13, 2025